KR900000078A - 필수 지방산 조성물 - Google Patents

필수 지방산 조성물 Download PDF

Info

Publication number
KR900000078A
KR900000078A KR1019890007946A KR890007946A KR900000078A KR 900000078 A KR900000078 A KR 900000078A KR 1019890007946 A KR1019890007946 A KR 1019890007946A KR 890007946 A KR890007946 A KR 890007946A KR 900000078 A KR900000078 A KR 900000078A
Authority
KR
South Korea
Prior art keywords
acid
drug
formulation
efa
essential fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890007946A
Other languages
English (en)
Other versions
KR0129666B1 (ko
Inventor
프레드릭 호로빈 대비드
Original Assignee
스테판 제랄드 웨트모어
에파몰 홀딩스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테판 제랄드 웨트모어, 에파몰 홀딩스 피엘씨 filed Critical 스테판 제랄드 웨트모어
Publication of KR900000078A publication Critical patent/KR900000078A/ko
Application granted granted Critical
Publication of KR0129666B1 publication Critical patent/KR0129666B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

필수 지방산 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. GLA와 n-6족 고급산에서 선택한 필수지방산 광, 스테아리돈산과 n-3족 고급산에서 선택된 필수지방산을 각산(each acid)10mg과 50g의 유효한 1일량으로 혼합시켜 정신분열증 및/또는 연합 지발성 운동장해를 처리하는 방법과 그 처리용 약물의 제제.
  2. 제1항에 있어서, 상기 n-6 EFA는 GLA, DGLA 및 AA에서 선택되고, 상기 n-3 EFA는 스테아리돈산, EPA, 22:5n-3및 DHA에서 선택됨을 특징으로한 상기 방법또는 약물의 제제.
  3. 제1항 또는 제2항에 있어서, 상기 EFAs에는 비타민 E를 상기산의 총량을 기준으로 하여 3wt%이상의 양으로 부가시킴을 특징으로 하는 상기 방법 또는 약물의 제제.
  4. 염증성분을 가진 피부질환을 처리하는 조성물, 방법 및 그 약물의 제제에 있어서, GLA와 n-6 족 고급산과 스테아리돈산 및 n-3조 고급산에서 선택된 필수지방산의 유효량은 상기 필수지방산을 기준으로하여 3wt%이상의 양으로 존재하는 비타민E를 국부제제에 혼합시킴을 특징으로 하는 상기 조성물, 방법 및 약물의 제제.
  5. 제4항에 있어서, 상기 n-6 과 n-3 의 EFA양자를 공존시킴을 특징으로 하는 상기 조성물, 방법 및 약물의 제제.
  6. 제5항에 있어서, 상기 n-6 EFA는 GLA, DGLA 및 AA에서 선택된, 상기 n-3 EFA는 스테아리돈산, EPA, 22:5n-3 및 DHA에서 선택함을 특징으로 하는 상기 조성물, 방법 또는 약물의 제제.
  7. 제4.,5 또는 제6항의 어느 한항에 있어서, 상기 염증질환은 과민성 급진, 건선, 좌창, 접촉피부염 또는 담마진임을 특징으로한 상기 조성물, 방법 또는 약물의 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007946A 1988-06-10 1989-06-09 필수지방산 조성물 Expired - Fee Related KR0129666B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888813766A GB8813766D0 (en) 1988-06-10 1988-06-10 Essential fatty acid compositions
GB88-13766.6 1988-06-10

Publications (2)

Publication Number Publication Date
KR900000078A true KR900000078A (ko) 1990-01-30
KR0129666B1 KR0129666B1 (ko) 1998-04-09

Family

ID=10638418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007946A Expired - Fee Related KR0129666B1 (ko) 1988-06-10 1989-06-09 필수지방산 조성물

Country Status (13)

Country Link
US (2) US4977187A (ko)
EP (2) EP0347056B1 (ko)
JP (1) JP2796838B2 (ko)
KR (1) KR0129666B1 (ko)
AT (1) ATE87825T1 (ko)
AU (2) AU618814B2 (ko)
CA (1) CA1334004C (ko)
DE (1) DE68905863T2 (ko)
ES (1) ES2053990T3 (ko)
GB (1) GB8813766D0 (ko)
IE (1) IE63303B1 (ko)
NZ (1) NZ229423A (ko)
ZA (1) ZA894380B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US6103755A (en) * 1990-05-22 2000-08-15 Bumann; Harold Foodstuff with prophylactic and/or healing effect and process for its production
DE69004081T2 (de) * 1990-05-23 1994-02-10 Nestle Sa Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
FR2679109B1 (fr) * 1991-07-18 1994-03-11 Institut Recherche Biologique Sa Nouveaux complements nutritionnels ou dietetiques anti-vieillissement a base d'acide gras poly-insature.
JPH07114761B2 (ja) * 1991-08-29 1995-12-13 ジェクス株式会社 皮膚清拭用品
US5436269A (en) * 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
EP0614359A1 (en) * 1991-11-26 1994-09-14 Warner-Lambert Company Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
JPH08511533A (ja) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
EP0734723A4 (en) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
DE69513172T2 (de) * 1994-06-22 2000-08-24 Asahi Kasei Kogyo K.K., Osaka Verfahren zur herstellung von methacrolein
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
DE69724629T2 (de) * 1996-06-03 2004-07-29 Croda International Plc., Goole Zusammensetzungen und deren verwendungen
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
ES2195175T3 (es) * 1996-10-11 2003-12-01 Scarista Ltd Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
GB9724783D0 (en) 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7138431B1 (en) * 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
AU2002318135B2 (en) * 2001-05-14 2007-08-02 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
WO2002092540A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
EP1450787A4 (en) * 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc FORMULATIONS AND METHODS FOR THE TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS
FR2833174B1 (fr) * 2001-12-06 2004-05-28 Margaret Bronnert Pommade grasse d'origine animale destinee a soulager des demangeaisons et irritations de la peau dues aux dermites, eczema atopique et psoriasis,secheresse cutanee et hyperkeratinose
US7163960B2 (en) 2002-03-08 2007-01-16 Monsanto Technology L.L.C. Treatment and prevention of inflammatory disorders
AU2003247685A1 (en) * 2002-07-02 2004-01-23 Galileo Pharmaceuticals, Inc. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004012753A1 (en) * 2002-07-31 2004-02-12 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
PL1656449T3 (pl) 2003-08-21 2009-08-31 Monsanto Technology Llc Desaturazy kwasów tłuszczowych z Primula
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
HRP20060326A2 (hr) * 2004-03-12 2007-02-28 Egis Gy�gyszergy�r Nyrt. Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
CA2562548C (en) 2004-04-16 2019-08-20 Monsanto Technology Llc Expression of fatty acid desaturases in corn
ATE469957T1 (de) 2004-11-04 2010-06-15 Monsanto Technology Llc Verfahren zur herstellung von ölzusammensetzungen
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
BR122018075948B1 (pt) 2006-03-10 2023-05-16 Monsanto Technology Llc Métodos de produzir uma planta de soja com teor de ácidos graxos de semente alterados
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
AU2008361645A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9480271B2 (en) 2009-09-15 2016-11-01 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
EP2708230B1 (en) 2011-05-12 2024-10-02 Nissui Corporation Composition for external skin use for inflammatory diseases
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
CN114410374B (zh) 2013-12-04 2025-01-07 株式会社日水 微生物油、微生物油的制造方法、浓缩微生物油及浓缩微生物油的制造方法
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
AU2022328181A1 (en) 2021-08-09 2024-03-21 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) * 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물

Also Published As

Publication number Publication date
AU618814B2 (en) 1992-01-09
DE68905863T2 (de) 1993-08-26
NZ229423A (en) 1992-10-28
ATE87825T1 (de) 1993-04-15
CA1334004C (en) 1995-01-17
AU7943491A (en) 1991-09-12
ES2053990T3 (es) 1994-08-01
KR0129666B1 (ko) 1998-04-09
ZA894380B (en) 1990-02-28
EP0454102A3 (en) 1992-01-02
IE891819L (en) 1989-12-10
JP2796838B2 (ja) 1998-09-10
US5120760A (en) 1992-06-09
JPH0232017A (ja) 1990-02-01
EP0454102A2 (en) 1991-10-30
EP0347056A1 (en) 1989-12-20
IE63303B1 (en) 1995-04-05
US4977187A (en) 1990-12-11
EP0347056B1 (en) 1993-04-07
AU3597489A (en) 1989-12-14
DE68905863D1 (de) 1993-05-13
GB8813766D0 (en) 1988-07-13
AU633442B2 (en) 1993-01-28

Similar Documents

Publication Publication Date Title
KR900000078A (ko) 필수 지방산 조성물
DE3926658C2 (de) Fettsäurezusammensetzung
JP4861606B2 (ja) 皮膚炎を治療するプロアントシアニジンを含む局所用医薬組成物
DE69100724T2 (de) Zusammensetzungen essentieller Fettsäuren und Therapie.
DE69534536T2 (de) Verwendung zur topischen anwendung von tocotrienol auf die haut und haare
DE68911103T2 (de) Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis.
DE3486339T2 (de) Pharmazeutische und diätetische Zusammensetzung.
DE69312579T2 (de) Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
DE3634152C2 (de) Neue kosmetische oder dermatologische Zusammensetzungen, die reich sind an gleichzeitig in Form der Triglyceride und in freier Form oder Salzform vorliegenden, essentiellen Fettsäuren
KR940021057A (ko) 흡연의 악영향을 완화시키기 위한 조성물
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
DE69806962T2 (de) FSNMU als entzündungshemmende Mittel in den oberflächen Geweben von Säugetieren
US5246726A (en) Iron-containing composition and method for treatment of cancer
AU595012B2 (en) Iron - containing composition and method for treatment of cancer
US5145686A (en) Topical pharmaceutical compositions
ATE258792T1 (de) Diät mit hohem lipidgehalt
DE69005062T2 (de) Fettsäuren zur Behandlung und Prävention von Hautschäden durch Radiotherapie.
DE69118130T2 (de) Nahrung
DE602004004880T2 (de) Hautpflegeprodukt mit tallöl-fettsäuren und pflanzenölen für trockene und schuppende haut und behandlung von psoriasis, dermatitis und ekzemen
DE4330664A1 (de) Verwendungen von Pflanzenölen
DE202004015931U1 (de) Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
DE4022815A1 (de) Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer hauterkrankungen
AU608571B2 (en) Composition and method for treatment of peptic ulcers
IE58919B1 (en) Pharmaceutical and dietary composition
DE3427193A1 (de) Verstaerkte venenmittel

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20041109

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20051113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20051113